RBT biotech company (BioTechnology Developments) plans to expand its portfolio of drugs and register the Betusphere adjuvant as an immunomodulator.
Preclinical studies of Betusphere are carried out at the Institute of Translational Medicine and Biotechnology of Sechenov University. Toxicity and immunotropic effects will be studied for up to 6 months. Then the company plans to obtain a permit to conduct clinical trials of the drug.
Currently, RBT is raising funds on the Rounds platform. The company plans to raise up to RUB 160 million. The funds will be used to expand the portfolio of vaccines developed by the company. For the investment procedure, please visit: https://rbiotech.ru/invest-rbt
According to RBT’s Director Igor Viktorovich Krasilnikov: “Betusphere is a new adjuvant for vaccines. We have already demonstrated its safety and effectiveness using previously developed vaccines. And now we plan to register Betusphere as a drug with immunomodulatory properties.”
Betusphere is a spherical virus-like particle obtained from a natural material, betulin. RBT uses Betusphere as an adjuvant for the development of candidate antiviral vaccines based on surface recombinant proteins. Such vaccines mimic the structure of viruses to stimulate a longer and more effective immune response. Previously, this platform was used to develop coronavirus vaccine Betuvax-Cov-2 and influenza vaccine TetraFluBET, as well as a pentavalent combination vaccine against influenza and coronavirus developed jointly with the Nacimbio pharmaceutical holding. The company’s pipeline also includes a human papillomavirus vaccine. Previous studies have shown that Betusphera increases the immunogenicity of vaccines several times.
RBT is a company of the Human Stem Cell Institute group (HSCI, MOEX: ISKJ), a resident of Skolkovo and Medtech Moscow, the Moscow Center for Innovative Technologies in Healthcare Technopark.